Company / Gross Margin
Acadia Pharmaceuticals Gross Margin History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
94.3%
FY2023
5-year range
94.3% / 98.0%
FY2019-FY2023
Trend
-3.8%
vs FY2022
Sector context
#1 of 28
Health Care
What the data says
Among 28 Health Care companies, Acadia Pharmaceuticals is in the top 4% for gross margin. Declined from 97.8% to 94.3% over the past 2 years.
Based on SEC 10-K filings.
94.3% in FY2023 with a 5-year CAGR of -0.2%. Ranks 1st among 28 companies in Health Care.
Declined from 97.8% to 94.3% over the past 2 years.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- -3.4pp
- 5-Year Change
- -0.2pp
- 10-Year Change
- -
Sector benchmark
Top 4% in Health CareTop 4% of 28This company 94.3% Sector average 60.3%
▼
+56.3% above sector average
Key checks
Key Insights
- In FY2023, gross margin decreased 3.8% year-over-year.
- Currently 34.0pp above the Health Care sector average.
- Peak gross margin was recorded in FY2022.
- Lowest gross margin in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | 94.3% | -3.8% |
| FY2022 | 98.0% | +0.3% |
| FY2021 | 97.8% | +0.1% |
| FY2020 | 97.7% | +1.1% |
| FY2019 | 96.7% | +2.3% |
| FY2018 | 94.5% | +1.9% |
| FY2017 | 92.7% | +12.8% |
| FY2016 | 82.2% | - |
As of FY2023 · SEC 10-K · Updated Jul 1, 2026